Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: Amgen; a smoking stock?

This article was originally published in Scrip

Executive Summary

The first major biotech company announced first quarter 2011 earnings on 20 April and then on 21 April announced that it would pay its first dividend, although not quite yet. That one of the buttresses underpinning the biotechnology firmament is paying money to shareholders should have ramifications, at least of a philosophical nature, across the entire biotech and pharmaceutical landscape. While investors and analysts were focussed on the progress of Amgen’s most recently launched drug for bone cancer denosumab (Xgeva), the news that Amgen was to break the habit of a lifetime might leave investors and entrepreneurs, well, ... gasping.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts